Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award - Priority Announcement - HIV/AIDS and/or STBBI

Direct Payment

$120,000.00

Host Immune Predictors of HIV Control After Treatment Interruption in Pediatric and Adult Populations

EF 2024-25

Résumé
Antiretroviral therapy (ART) has transformed HIV treatment, enabling effective viral suppression and significantly improving the health outcomes for people living with HIV. However, ART does not completely eliminate HIV, which hides in infected cells and causes the virus to reemerge when treatment stops, requiring lifelong ART to maintain control. A rare group of individuals known as post-treatment controllers (PTCs), observed in both children and adults, can maintain viral suppression after discontinuing ART, providing valuable insights for HIV cure research. While previous work has identified important immune functions and demonstrated differences in the immune responses of adult and pediatric PTCs, the exact mechanisms behind their ability to control the virus are still unclear. Recent studies suggest that broadly neutralizing antibodies (bNAbs) may offer a promising alternative to ART, as they can block HIV and enhance the immune system to target infected cells, similar to a vaccine, although their effectiveness in individuals varies. This project aims to identify and compare the key immune factors associated with sustained viral suppression after they stop taking ART in both spontaneous PTCs and individuals undergoing bNAb therapy. By analyzing blood samples from bNAb clinical trials and large cohorts of HIV-infected adults and children with monitored treatment interruptions, I will investigate the function of key immune cells involved in successful viral control and identify common characteristics across these populations. This project will combine immunology, virology, and genomics to inform the development of optimized bNAb therapies for long-term HIV control and advance efforts toward achieving HIV cure.
Programme
Doctoral Research Award - Priority Announcement - HIV/AIDS and/or STBBI
Bénéficiaire
Emplacement
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
517760
Name
Edgar Julia E
Country
United Kingdom
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Host Immune Predictors of HIV Control After Treatment Interruption in Pediatric and Adult Populations
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - Priority Announcement - HIV/AIDS and/or STBBI
Keyworddelim
Antiretroviral Therapy (Art); Broadly Neutralizing Antibodies (Bnabs); Human Immunodeficiency Virus (Hiv); Immune Sex Differences; Post-Treatment Controllers; Remission; Treatment Interruption; Vaccinal Effect
Abstract
Antiretroviral therapy (ART) has transformed HIV treatment, enabling effective viral suppression and significantly improving the health outcomes for people living with HIV. However, ART does not completely eliminate HIV, which hides in infected cells and causes the virus to reemerge when treatment stops, requiring lifelong ART to maintain control. A rare group of individuals known as post-treatment controllers (PTCs), observed in both children and adults, can maintain viral suppression after discontinuing ART, providing valuable insights for HIV cure research. While previous work has identified important immune functions and demonstrated differences in the immune responses of adult and pediatric PTCs, the exact mechanisms behind their ability to control the virus are still unclear. Recent studies suggest that broadly neutralizing antibodies (bNAbs) may offer a promising alternative to ART, as they can block HIV and enhance the immune system to target infected cells, similar to a vaccine, although their effectiveness in individuals varies. This project aims to identify and compare the key immune factors associated with sustained viral suppression after they stop taking ART in both spontaneous PTCs and individuals undergoing bNAb therapy. By analyzing blood samples from bNAb clinical trials and large cohorts of HIV-infected adults and children with monitored treatment interruptions, I will investigate the function of key immune cells involved in successful viral control and identify common characteristics across these populations. This project will combine immunology, virology, and genomics to inform the development of optimized bNAb therapies for long-term HIV control and advance efforts toward achieving HIV cure.
Competitiondate
202410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Edgar, Julia E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~